- Home
- AU vs RVMD Comparison
AU vs RVMD Comparison
Compare AU & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AU
- RVMD
- Stock Information
- Founded
- AU 1944
- RVMD 2014
- Country
- AU United States
- RVMD United States
- Employees
- AU N/A
- RVMD N/A
- Industry
- AU Precious Metals
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AU Basic Materials
- RVMD Health Care
- Exchange
- AU Nasdaq
- RVMD Nasdaq
- Market Cap
- AU 10.3B
- RVMD 8.7B
- IPO Year
- AU 1972
- RVMD 2020
- Fundamental
- Price
- AU $23.69
- RVMD $44.39
- Analyst Decision
- AU Hold
- RVMD Strong Buy
- Analyst Count
- AU 5
- RVMD 12
- Target Price
- AU $31.75
- RVMD $64.67
- AVG Volume (30 Days)
- AU 4.4M
- RVMD 2.1M
- Earning Date
- AU 11-07-2024
- RVMD 11-06-2024
- Dividend Yield
- AU 0.93%
- RVMD N/A
- EPS Growth
- AU N/A
- RVMD N/A
- EPS
- AU 1.34
- RVMD N/A
- Revenue
- AU $5,299,000,000.00
- RVMD $742,000.00
- Revenue This Year
- AU $31.43
- RVMD N/A
- Revenue Next Year
- AU $27.65
- RVMD $1,855.42
- P/E Ratio
- AU $17.66
- RVMD N/A
- Revenue Growth
- AU 17.78
- RVMD N/A
- 52 Week Low
- AU $15.80
- RVMD $25.93
- 52 Week High
- AU $32.57
- RVMD $62.40
- Technical
- Relative Strength Index (RSI)
- AU 40.89
- RVMD 34.18
- Support Level
- AU $23.20
- RVMD $42.53
- Resistance Level
- AU $23.98
- RVMD $44.22
- Average True Range (ATR)
- AU 0.65
- RVMD 1.59
- MACD
- AU -0.12
- RVMD -0.27
- Stochastic Oscillator
- AU 14.94
- RVMD 28.46
About AU AngloGold Ashanti PLC
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.